Currently Enrolling
Asthma
Phase 2
Study ID: C4531029

Moderate to Severe Asthma — Pfizer

Sponsored by Pfizer Inc.

Official Study Title
A phase 2, randomized, double-blind, placebo-controlled, parallel-group, dose-Ranging study to investigate the efficacy and safety of pf-07275315 in adult Participants with inadequately controlled moderate-to-severe asthma
Sponsor
Pfizer Inc.
Phase
Phase 2
Indication
Moderate-to-Severe Asthma
Duration
About 38 weeks
About This Study

Objective

The purpose of the study is to evaluate the efficacy and safety of PF-07275315 in participants with inadequately controlled moderate-to-severe asthma, and to provide a preliminary assessment of dose-response.

Who Can Participate

Key Eligibility Criteria

Below are the main inclusion and exclusion criteria for this study. The full eligibility assessment will be discussed with you by our research team during screening.

Key Inclusion Criteria

  • Adults ≥18 years
  • Documented diagnosis of moderate-to-severe asthma
  • Inadequately controlled asthma despite medium-to-high dose inhaled corticosteroids plus controller
  • Baseline eosinophil count eligibility (≥300 cells/µL for primary analysis population)
  • Demonstrated reversible airway obstruction
  • Stable asthma therapy prior to screening
  • Able to complete spirometry and PRO assessments
  • History of persistent, moderate-to-severe asthma for at least 12 months prior to screening and have experienced at least 1 asthma exacerbation requiring treatment with systemic steroids (oral or parenteral) for 3 days or more within 12 months of the screening visit

Key Exclusion Criteria

  • Current smokers or excessive smoking history
  • Diagnosis of COPD or other chronic lung disease
  • Recent asthma exacerbation requiring systemic steroids
  • Prior or current biologic therapy within washout period
  • Clinically significant cardiovascular, renal, hepatic, or immunologic disease
  • Active infection (TB, hepatitis, HIV)
  • History of malignancy (with limited exceptions)
  • Pregnancy or breastfeeding
  • Use of prohibited concomitant medications
Get Started

Apply for this study

Fill out the form below to see if you qualify. Our research coordinators will contact you directly to discuss your eligibility — there's no obligation to participate.

Your information is kept confidential and only used for study eligibility purposes.

Research team discussing clinical study data in laboratory
Why Participate

Advancing research, one participant at a time.

Clinical trials depend on volunteers like you. By participating, you gain access to potential new treatments while helping researchers discover safer, more effective therapies for everyone.

  • Access to investigational treatments and expert medical care
  • Close monitoring by our experienced research team
  • Contribute to better treatments for future patients
  • Confidential — your information is protected at every step